2-(2-pyridyl)-5-(3-cyanophenyl)-1,3,4-triazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2-pyridyl)-5-(3-cyanophenyl)-1,3,4-triazole
• 英文别名: 2-(pyridin-2-yl)-5-(3-cyanophenyl)-1,3,4-triazole；3-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)benzonitrile
• 化学式: C₁₄H₉N₅
• 分子量: 247.259
• InChiKey: JOGBPNKJCHPTAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氰基吡啶 、 钠 、 3-氰基苯肼 在 甲苯 作用下， 以 甲醇 为溶剂， 反应 20.0h， 以afforded 0.12 g (26%) of 2-(2-pyridyl)-5-(3-cyanophenyl)-1,3,4-triazole的产率得到2-(2-pyridyl)-5-(3-cyanophenyl)-1,3,4-triazole
  参考文献：
  名称：

  Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

  摘要：

  本发明提供了一种在代谢型谷氨酸受体上表现为拮抗剂的化合物和制药组合物，可用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。

  公开号：

  US20050154027A1

文献信息

• HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1379525A2

  公开（公告）日：2004-01-14
• NEW USE
  申请人：AstraZeneca AB

  公开号：EP1896011A1

  公开（公告）日：2008-03-12
• METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE
  申请人：Pharmalundensis AB

  公开号：EP2672971A1

  公开（公告）日：2013-12-18
• New use
  申请人：Lehmann Anders

  公开号：US20070010553A1

  公开（公告）日：2007-01-11

  The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment or prevention of cough.
• Light emission material and organic electroluminescent device using the same
  申请人：Wu Pei-Chi

  公开号：US20060286404A1

  公开（公告）日：2006-12-21

  An organic electroluminescent device including a substrate, an anode, a cathode, a hole transport layer, an electron transport layer and an emission layer is provided. The anode and the cathode are disposed on the substrate. The hole transport layer is disposed between the anode and the cathode. The electron transport layer is disposed between the hole transport layer and the cathode. The emission layer is disposed between the hole transport layer and the electron transport layer. The chemical structure of the dopant is represented by formula [I]: “M” represents a metal atom, m is smaller than or equal to the ligand number of “M”, n is smaller than m. “Y1” is selected from aryl or heteroaryl. “Y2” and “Y3” are respectively selected from nitro-containing heterocyclic ring. “X”, “R1”, “R2” and “R3” are respectively selected from any substituent group or hydrogen. “A” is selected from aryl, heteroaryl or nitro-containing heterocyclic group.